Stock Ratings / Health Care / AUTL / news

ALLO (38) CCCC (27) TECX (37) PROK (44) ⌘ Pro Terminal →

Why AUTL Stock dropped -3.07% Today — RQD Quant Desk Flash

$1.58 -3.07% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Autolus Therapeutics plc (AUTL) carries a Roarable Rating of E (Strong Sell) with 25/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $420.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-14.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AUTL)Realized 20D OHLCV Swing Band: ±11.9%

AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why AUTL Stock dropped -3.07% Today — RQD Quant Desk Flash

Autolus Therapeutics plc (AUTL) dropped -3.07% to $1.58, trading at 29% of its 52-week range ($1.18 – $2.58). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

▸Technical Tape: Trading at 29% of its 52-week range ($1.18 – $2.58) with RSI-14 at 36.6 (NEUTRAL RANGE).
▸Volatility Profile: Historical 20-day realized swing band of ±11.9% around $1.58 (no active unusual options sweep snapshot on file).
▸Fundamental Anchor: Roarable E (Strong Sell) backed by 0% gross margin and $0 annual free cash flow.

Live AUTL Headlines & Catalysts

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AUTL)

✓Walkthrough of AUTL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AUTL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +12.06%📐 HORIZONTAL RANGE

2026-10-30O $1.58H $1.59L $1.48C $1.58VOL 1.67M

RES: $3.08SUP: $1.38SMA50: $1.91SMA200: $1.67

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AUTL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AUTL Butterfly Map → + Track AUTL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AUTL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AUTL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AUTL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AUTL)

Health Care Rank #989 of 1016 ⚔️ ALLO vs AUTL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AUTL vs. ALLO, CCCC, TECX, PROK)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Autolus Therapeutics plc (AUTL) ranks #989 by composite RQD confidence (25/100, grade E) and #473 by equity capitalization ($420.5M). Within this direct 5-issuer industry benchmark cohort, AUTL leads on earnings valuation at N/A trailing P/E, while AUTL leads on capital efficiency and profitability with -35.0% ROIC and -27.8% gross margin. PROK currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with AUTL at 25/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AUTL ACTIVE Autolus Therapeutics plc	E	25/100	—	-27.8%	-35.0%	-3.07%	$420.5M	Benchmark Subject
ALLO Allogene Therapeutics Inc.	D-	38/100	—	—	-35.0%	-3.85%	$431.9M	/allo-vs-autl →
CCCC C4 Therapeutics Inc.	E	27/100	—	—	-35.0%	-2.80%	$406.0M	/cccc-vs-autl →
TECX Tectonic Therapeutic Inc.	D-	37/100	—	—	-35.0%	-0.29%	$400.8M	/tecx-vs-autl →
PROK ProKidney Corp. (Class A)	D	44/100	—	—	-35.0%	-3.29%	$444.4M	/prok-vs-autl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001730463

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Autolus Therapeutics plc (AUTL) reported GAAP revenue of $75.4M (+644.9% vs. FY2024 revenue of $10.1M , and +4339.8% cumulative change since FY2023) , GAAP net income of -$287.5M, operating cash flow of -$283.6M, and free cash flow of -$302.6M (-32.5% YoY). On the balance sheet, AUTL closed FY2025 with $589.1M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$75.4M	-$287.5M	-$283.6M	-$302.6M	$589.1M	—
FY2024 (FY)	2024-12-31	$10.1M	-$220.7M	-$206.3M	-$228.3M	$782.7M	—
FY2023 (FY)	2023-12-31	$1.7M	-$208.4M	-$145.6M	-$145.6M	—	—

3. AUTL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AUTL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Autolus Therapeutics plc (NASDAQ: AUTL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $1.58 (-3.07% 1D, market cap $420.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AUTL ranks #989 in composite RQD confidence.

How does AUTL compare to ALLO and CCCC in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AUTL carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of -27.8%, and ROIC of -35.0%. By comparison, ALLO (Allogene Therapeutics Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $431.9M) and CCCC (C4 Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $406.0M). Among the 5-stock peer group, AUTL leads on earnings multiple (N/A) while AUTL leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AUTL?

Per AUTL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001730463), Autolus Therapeutics plc generated $75.4M in revenue (+644.9% YoY), -$287.5M in net income, and -$302.6M in free cash flow against $589.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AUTL trading relative to its 50-day, 200-day, and 52-week technical levels?

AUTL last traded at $1.58 (-3.07% on volume of 2,347,079 shares), positioning the stock -17.28% below its 50-day simple moving average ($1.91) and -5.39% below its 200-day simple moving average ($1.67). Across its 52-week range of $1.18 to $2.58, AUTL sits at the 28.6% percentile with a 14-day RSI of 36.6 (NEUTRAL RANGE) and an implied next-earnings move of ±11.9% ($1.39 to $1.77).

AUTL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Why is AUTL stock moving today?

Why AUTL Stock dropped -3.07% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

Direct Sub-Reports: AUTL RQD Cockpit AUTL 12M Forecast AUTL Earnings & Move AUTL Dividends & DRIP AUTL Insiders & 13F AUTL Whale Options AUTL Profit Sankey AUTL News & Why